Lifeward Ltd.

Lifeward, formerly ReWalk Robotics, builds technology for people with physical limitations and for the clinicians who support them. Its principal commercial products are the ReWalk Personal Exoskeleton for selected people with spinal-cord injury, AlterG Anti-Gravity systems for reduced-load gait and physical training, and MYOLYN MyoCycle functional electrical stimulation cycles for home and clinical use. The company’s portfolio therefore combines powered lower-limb robotics, body-weight offloading, and electrical muscle stimulation rather than representing a single exoskeleton product. The company’s website now promotes ReWalk 7, while its 2025 Form 10-K identifies ReWalk, AlterG, and MyoCycle as the main revenue products and says Lifeward is no longer actively commercializing ReStore.

The technical value is in making human-machine assistance safe and repeatable in a clinical or home setting. Relevant capabilities include powered joint actuation, gait and user-intent sensing, configurable assistance, functional electrical stimulation, pneumatic body-weight support, patient fitting, clinician supervision, and safety interlocks. These systems operate under stringent constraints: the device must assist a user without destabilizing them, tolerate variation in gait and impairment, and fit into therapy workflows that measure progress and manage liability. That is meaningful deep-tech experience, although the product mix is more medical-device engineering and clinical workflow integration than general-purpose autonomous robotics.

Lifeward sells through rehabilitation hospitals, outpatient clinics, physical-therapy and sports-medicine organizations, distributors, physicians, and selected home users. The demand case is supported by persistent needs in spinal-cord injury, stroke, neurological disease, orthopedic recovery, and mobility maintenance, but the market is difficult to scale. Clinical evidence, therapist training, device fitting, service coverage, payer decisions, and capital budgets all influence adoption. Medicare and Medicare Advantage payment developments for ReWalk are constructive adoption signals, but the company’s filing also describes long collection cycles for some CMS payments, reliance on a small customer base, recurring losses, and substantial doubt about its ability to continue as a going concern. Its reported 81 employees as of December 31, 2025 also makes the old 100-200 range too broad.

Competition includes Ekso Bionics in powered exoskeletons, CYBERDYNE in wearable gait-assist systems, Wandercraft in self-stabilizing exoskeletons, Hocoma in robotic gait-training systems, Bionik in rehabilitation robotics, and AlterG alternatives in reduced-load treadmill therapy. Lifeward’s differentiation is a relatively broad rehabilitation portfolio and accumulated experience with reimbursement, patient case management, clinical training, and regulated commercialization. That breadth may support cross-selling and a continuum-of-care proposition, but it also creates product-support complexity and does not remove the need to prove utilization, outcomes, gross-margin improvement, and durable financing.

The defense and security case is credible but indirect. Powered mobility, gait sensing, human-in-the-loop controls, and rehabilitation workflows could inform military recovery, veteran care, human-performance research, and casualty-rehabilitation programs. The products are not presented as field-ready military equipment, and the company’s public materials do not establish operational defense deployments. Military use would require redesign for ruggedization, contamination, load carriage, battery endurance, maintainability, cyber resilience, and operation outside supervised clinical environments. Lifeward is consequently more valuable as a mature medical-robotics reference or potential specialist partner than as a turnkey defense platform or early-stage startup.